Intervacc is trading at €0.06 (-18.14%) after the September 16, 2026 session, with the decline appearing more consistent with weak biotech-sector sentiment than fresh corporate news.
- No new company-specific announcement, earnings release, regulatory action, or transaction was identified for September 17, 2026.
- The latest clearly identified company announcement was a July 30 EMA application concerning Strangvac’s immunity duration.
- Broader biotech weakness was reported alongside the decline.